CRISPR Gene Therapy 2026: The Clinical Trials Changing Medicine

CRISPR Has Crossed the Clinic

When Jennifer Doudna and Emmanuelle Charpentier won the Nobel Prize for CRISPR in 2020, the technology was still mostly a research tool. Six years later, in 2026, CRISPR-based gene therapies are no longer theoretical. They are real, approved, and being infused into patients at hospitals around the world.

The first FDA-approved CRISPR therapy, Casgevy (exagamglogene autotemcel), was greenlit in late 2023 for sickle cell disease and beta-thalassemia. Since then, the pipeline has exploded. As of mid-2026, more than 200 CRISPR-based clinical trials are active globally, and the FDA has cleared several additional therapies for accelerated review.

Here is where CRISPR medicine actually stands in 2026, which trials matter, and what patients can realistically access now.

The Diseases CRISPR Is Actually Treating in 2026

Sickle Cell Disease and Beta-Thalassemia

Casgevy remains the headline therapy. Vertex and CRISPR Therapeutics report durable results, with most patients remaining transfusion-independent three years after a single infusion. The catch: the price tag is around $2.2 million per patient, and the treatment requires months of preparation including chemotherapy and stem cell harvesting.

A second therapy, Lyfgenia (lovo-cel) from bluebird bio, was approved in 2023 and continues to compete in the same space. Both therapies function by editing the patient's own bone marrow stem cells ex vivo, then reinfusing them after myeloablative conditioning.

In 2026, the conversation is shifting from approval to access. The CDC estimates around 100,000 Americans live with sickle cell disease, but fewer than 200 had received Casgevy through early 2026 due to cost and the complexity of the treatment centers required.

Transthyretin Amyloidosis

The next big CRISPR approval came in late 2024, when the FDA approved Verve Therapeutics' in vivo CRISPR therapy, known as VERVE-101 (later branded as Vervex), for transthyretin amyloidosis, a hereditary heart disease. Unlike Casgevy, VERVE-101 is a one-time intravenous infusion that edits liver cells directly inside the body, no stem cell harvesting required.

This was the first in vivo CRISPR approval in the US, a major technical milestone. Phase 2 data showed TTR protein reductions of more than 90% with a single dose. The 2026 rollout is being watched closely by every gene therapy company working on in vivo approaches.

Inherited Blindness

Editas Medicine's EDIT-101 (renamed Editas-101) received conditional approval for Leber congenital amaurosis type 10, a rare form of childhood blindness, in late 2025. The therapy delivers CRISPR directly to the retina via subretinal injection. Early data shows meaningful vision restoration in roughly 40% of treated patients.

Several competing programs are also targeting inherited retinal diseases, including ones from Beam Therapeutics and Intellia Therapeutics.

The Active Clinical Trial Pipeline in 2026

Hundreds of CRISPR trials are ongoing. The ones generating the most buzz in 2026 cluster into a few categories.

Cancer Immunotherapy

The most active area is CRISPR-engineered cell therapies for cancer. The approach: extract a patient's T cells, use CRISPR to knock out genes that limit immune function (like PD-1) or add a chimeric antigen receptor (CAR), then reinfuse the edited cells.

CRISPR Therapeutics, Allogene, and Caribou Biosciences all have programs in solid tumors, where CAR-T has historically struggled. Early 2026 data from Caribou's allogeneic CAR-T program showed response rates around 60% in patients with relapsed B-cell lymphoma, with much shorter manufacturing timelines than autologous CAR-T therapies.

Cardiovascular Disease

Verve is running additional trials targeting PCSK9 (the same gene targeted by Repatha and Praluent, but with a one-time edit instead of lifelong injections). The trial targets heterozygous familial hypercholesterolemia, and the company reported durable LDL cholesterol reductions of around 70% in Phase 1.

Beam Therapeutics is also advancing base-editing programs for alpha-1 antitrypsin deficiency and sickle cell disease, with early 2026 data showing promise.

Rare Metabolic Diseases

Intellia Therapeutics is running trials for hereditary angioedema, where a single in vivo CRISPR dose reduced attack frequency by more than 80% in early data. This is one of the most-watched programs because hereditary angioedema has existing effective treatments, so the bar to beat is real.

Prime Medicine is developing prime editing (a more precise CRISPR offshoot) for chronic granulomatous disease and other rare metabolic disorders.

HIV Cure Research

Several academic groups, including ones at UCSF and Temple University, are pursuing CRISPR-based approaches to excise dormant HIV from infected cells. The work is still preclinical but is generating optimism that a functional cure may be possible within the decade.

The Big Technical Challenges Remaining

Despite the progress, several challenges keep CRISPR from being a default treatment option.

Delivery

The hardest problem is getting CRISPR components into the right cells. For liver targets, lipid nanoparticles (similar to the technology used in mRNA COVID vaccines) have largely solved the problem. For brain, heart, and muscle tissue, delivery remains a major hurdle. Researchers are exploring adeno-associated virus (AAV) vectors, engineered exosomes, and even physical methods like ultrasound-mediated delivery.

Off-Target Edits

CRISPR can occasionally cut DNA in unintended locations, which could potentially cause cancer or other problems. The newer generation of editors (base editors and prime editors) substantially reduces off-target effects, but they are not zero. Regulatory agencies require extensive off-target profiling before approving any new therapy.

Immunogenicity

The CRISPR Cas9 protein is derived from bacteria, and some patients have pre-existing immune responses that could limit effectiveness or cause side effects. Newer editors derived from different bacterial species (Cas12, Cas13) may bypass some of these immune issues.

Manufacturing and Cost

Casgevy costs more than $2 million per patient. Even with scaling, CRISPR therapies will not be cheap anytime soon. The healthcare system is still figuring out how to pay for one-time curative treatments that potentially replace lifelong drug regimens. Outcome-based payment models are being piloted.

Where to Watch in the Next 18 Months

A few key things to watch through the rest of 2026 and into 2027.

First, the rollout of Vervex. In vivo CRISPR for a chronic disease is a fundamentally different model from Casgevy. If the real-world results match the Phase 2 data, it could open the door to dozens of new in vivo programs.

Second, the first FDA decisions on base editors. Beam Therapeutics is expected to file for approval of its base editing therapy for sickle cell disease in late 2026, which could be the first approved base editor.

Third, regulatory clarity on heritable edits. As of 2026, clinical use of heritable human germline editing remains effectively banned in most jurisdictions, but the WHO published a framework in 2024 that may open the door for tightly controlled research. No human embryos with edited germlines have been implanted, but the conversation is happening.

Fourth, China. Several Chinese biotechs are running aggressive CRISPR programs and have reported results in cancer and HIV. The regulatory pathway in China is faster, which means data may emerge there first on some applications.

The Bottom Line

CRISPR in 2026 is a real medicine, not a future promise. Patients with sickle cell disease, beta-thalassemia, transthyretin amyloidosis, and certain inherited blindness conditions can access approved therapies. Hundreds of additional trials are expanding the list of treatable conditions every year.

The remaining challenges, especially around delivery, cost, and access, are solvable but will take years. For now, the technology has crossed the threshold from experimental to clinical, and the pace of new approvals is accelerating.